<DOC>
	<DOCNO>NCT02232529</DOCNO>
	<brief_summary>The aim study ass MIN-101 take body give different amount different formulation . The drug give single dose Part 1 study Part 2 study multiple dose , daily 7 day . The ultimate aim find optimal formulation develop daily dose treatment schizophrenia .</brief_summary>
	<brief_title>Pharmacokinetic Study MIN-101 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy male ( Part 1 Part 2 ) nonpregnant , nonlactating healthy female ( Part 2 ) Body mass index ( BMI ) 18.0 30.0 kg/m2 Must CYP2D6 Extensive metabolizer Must willing able communicate participate whole study Must provide write informed consent Must agree use adequate method contraception Key Subjects QTc &gt; 430 male , &gt; 450 female confirm repeat ECG Any family history sudden cardiac death Torsade de Points No personal family history unexplained presyncope , syncope orthostatic hypotension History drug alcohol abuse past 2 year History evidence medically diagnose clinically significant psychiatric disorder Suicidal tendency history suicidal attempt Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = Â½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen Females childbearing potential pregnant lactating ( female subject must negative urine pregnancy test admission ) Clinically significant abnormal biochemistry , haematology urinalysis judge investigator Positive drug abuse test result Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>modify release formulation</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>